School of Medicine
Showing 1-5 of 5 Results
-
Melinda L. Telli, M.D.
Professor of Medicine (Oncology)
Current Research and Scholarly InterestsMy research focuses on the development of novel therapies for the treatment of triple-negative and hereditary cancer. Other areas of interest include prevention of cardiac damage associated with breast cancer treatment and cardiotoxicity of anti-cancer agents.
-
Stefano Testa
Instructor, Medicine - Oncology
BioDr. Testa is a medical oncologist and physician-scientist specializing in cellular therapy and the care of patients with soft tissue and bone sarcomas. He earned his medical degree from the University of Naples Federico II in Naples, Italy. He subsequently moved to the United States and conducted research in the laboratory of Dr. Ronald Levy at Stanford University, where he studied intratumoral vaccination strategies and mRNA delivery platforms designed to target B cells and T cells in vivo. He completed his internal medicine residency at Stanford University, followed by a fellowship in hematology and oncology at Beth Israel Deaconess Medical Center. Dr. Testa’s research focuses on identifying targets for adoptive T-cell therapies in solid tumors, particularly soft tissue and bone sarcomas, and on novel synthetic biology approaches to enhance the effectiveness of T-cell therapies against solid tumors.
-
Haluk Tezcan, MD
Adjunct Clinical Associate Professor, Medicine - Oncology
BioClinical focus:
Breast Oncology
Molecular Diagnostics
Dr. Tezcan is a medical oncologist and hematologist with over three decades of diverse experience in cancer management and research.
He is leading the clinical development of Droplet Biosciences' novel liquid biopsy technology, a first-in-class lymphatic fluid molecular residual disease assessment, overseeing the scientific and clinical development of the technology. With over three decades of direct patient care and clinical trial experience as a principal investigator and director, both in academia and private practice, he has a firsthand understanding of the unmet clinical needs of physicians and patients, as well as broad experience in clinical trial design and implementation.
He is also co-principal at Athea Oncology, guiding practices and hospitals in developing clinical trial programs and high-value real-world data collection and diagnostic companies in clinical development. He is also a reviewer of JCO Precision Medicine.
Before joining Athea Oncology and Droplet Biosciences, he was the co-founder of LexentBio, which was successfully acquired by Roche/FMI. He also served as Director of Translational Medicine at Genomic Health and as Vice President, leading oncology development at Counsyl, where he integrated science with clinical product development. He established the CA.RE.foundation, a cancer research foundation dedicated to enabling the execution of clinical trials across community oncology sites throughout the Northwest US. He has independently built multiple software tools to help oncologists navigate the practical realities of their daily work.
